首页> 美国卫生研究院文献>BMC Cardiovascular Disorders >Efficacy and safety of alirocumab a fully human PCSK9 monoclonal antibody in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

【2h】

Efficacy and safety of alirocumab a fully human PCSK9 monoclonal antibody in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

机译：完全人源PCSK9单克隆抗体Alirocumab在高耐受性他汀类药物最大耐受剂量下对高胆固醇血症控制不良的高心血管风险患者的疗效和安全性：ODYSSEY COMBO I和II试验的原理和设计

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundAlirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events.

机译：背景Alirocumab是一种针对人蛋白原转化酶枯草杆菌蛋白酶kexin 9型（PCSK9）的完全人单克隆抗体，正在研究中，用于治疗高胆固醇血症和减少心血管事件。

著录项

期刊名称 BMC Cardiovascular Disorders
作者
Helen M Colhoun; Jennifer G Robinson; Michel Farnier; Bertrand Cariou; Dirk Blom; Dean J Kereiakes; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari;
展开▼
作者单位

展开▼
年(卷),期 2014(14),-1
年度 2014
页码 121
总页数 10
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
Alirocumab Ezetimibe Low-density lipoprotein cholesterol Monoclonal antibody Proprotein convertase subtilisin kexin type 9;

机译：Alirocumab;Ezetimibe;低密度脂蛋白胆固醇;单克隆抗体;Proprotein转化酶枯草杆菌蛋白酶kexin 9型;

相似文献

外文文献

1. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials [J] . Helen M Colhoun, Jennifer G Robinson, Michel Farnier, BMC Cardiovascular Disorders . 2014,第1期

机译：完全人源PCSK9单克隆抗体Alirocumab在高耐受性他汀类药物最大耐受剂量下对高胆固醇血症控制不良的高心血管风险患者的疗效和安全性：ODYSSEY COMBO I和II试验的原理和设计
2. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial [J] . Cannon Christopher P., Cariou Bertrand, Blom Dirk, European Heart Journal: The Journal of the European Society of Cardiology . 2015,第19期

机译：在最大耐受剂量的他汀类药物控制量不足的高胆固醇血症患者中，高心血管风险患者使用alirocumab的疗效和安全性：ODYSSEY COMBO II随机对照试验
3. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial [J] . Cannon Christopher P., Cariou Bertrand, Blom Dirk, European Heart Journal: The Journal of the European Society of Cardiology . 2015,第19期

机译：Alirocumab在高胆固醇血症患者高耐受剂量的血管内血管患者中的高血管患者的疗效和安全性：奥德赛组合II随机对照试验
4. Fast TrackEditors choice: Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial [O] . Christopher P. Cannon, Bertrand Cariou, Dirk Blom, -1

机译：Fast TrackEditor的选择：在最大耐受剂量的他汀类药物下高胆固醇血症控制不足的高心血管风险患者中alirocumab的疗效和安全性：ODYSSEY COMBO II随机对照试验
5. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials [O] . Colhoun, Helen M, Robinson, Jennifer G, Farnier, Michel, 2015

机译：完全人类PCSK9单克隆抗体Alirocumab在最大耐受剂量的他汀类药物治疗，高胆固醇血症控制不良的高心血管风险患者中的疗效和安全性：ODYSSEY COMBO I和II试验的原理和设计

Efficacy and safety of alirocumab a fully human PCSK9 monoclonal antibody in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅